Rosacea
Conditions
Brief summary
The purpose of this exploratory study is to assess the efficacy, safety and tolerability of DFD-04 Ointment for topical treatment of rosacea over 12 weeks of treatment.
Detailed description
Subjects with mild to moderate papulopustular rosacea (Investigator's Global Assessment \[IGA\] grade 2-3), a Clinician's Erythema Assessment (CEA) score of 2-3 and 6-30 inflammatory lesions (papules and pustules) were randomized to treatment with DFD-04 ointment or Vehicle ointment in a ratio of 2:1. During the 12-week treatment period subjects used the IMP twice daily with approximately 12 hours between applications. Subjects were instructed to treat affected skin in a defined treatment area on the face. The investigator assessed efficacy by using an IGA 5-point scale and CEA 4-point scale and by counting the number of inflammatory lesions on the face at Baseline (Day 1) and Weeks 4, 8 and 12 (End of Treatment \[EoT\], defined as complete clearance of inflammatory lesions or Week 12, whichever was earlier). Furthermore, a non-invasive biomarker assessment was done by using a Transdermal Analysis Patch (TAP) at Baseline (Day 1) and Weeks 4 and 12. Safety assessments included investigator's assessment of application site reactions at Baseline (Day 1) and Weeks 4, 8, and 12 for all treated areas. Other safety assessments included vital signs (blood pressure \[BP\] and pulse rate) and urine pregnancy tests (UPTs) (only for females), clinical laboratory parameters (serum and urine), extent of exposure, and Adverse Events. In addition, pharmacokinetic (PK) analysis was performed to evaluate the systemic exposures of itraconazole and its active metabolite, hydroxyl-itraconazole, with blood samples drawn from the first 12 subjects at various pre-specified timepoints.
Interventions
DRUGDFD-04 Ointment
OTHERPlacebo Ointment
Sponsors
Dr. Reddy's Laboratories Limited
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 64 Years
Healthy volunteers
No
Inclusion criteria
1. Subjects must be able to understand the requirements of the study and be willing to give written informed consent. 2. Subjects must be willing to provide authorization to use protected health information. 3. Subjects, any gender or race, must be in good general health as determined by the Investigator 4. Subjects must have a clinical diagnosis of papulopustular rosacea, Investigator's Global Assessment (IGA) grade 2 - 3. 5. Subjects must have 6 - 30 inflammatory lesions (papules and pustules) of rosacea over the face. 6. Subjects must have a Clinician's Erythema Assessment (CEA) score of 2 - 3. 7. Subjects must have no more than 2 nodules. 8. Subjects must agree to only use the study products and to not use any other treatment for rosacea (prescription or over the counter) or any other skin care or cosmetics product (make-up etc.) on the facial skin of the treatment area during the course of the study. 9. Subjects must be free of any systemic or dermatologic disorder, which in the opinion of the Investigator, will interfere with the study results. 10. Females have a negative urine pregnancy test at the Screening and Baseline Visit. 11. Females must either be postmenopausal with no menses for at least 12 months or surgically sterile (hysterectomy or tubal ligation) or agree to use a reliable method of contraception with a failure rate of less than 1 percent per year when used consistently and correctly. 12. Subject must be in good general health as determined by the investigator and supported by the medical history and normal or not clinically significant abnormal vital signs (blood pressure and pulse). 13. Subject is physically able to apply study product to all affected areas.
Exclusion criteria
1. Females who are pregnant or nursing or planning to become pregnant during the study. 2. Subjects who have been treated for rosacea within the 30 days prior to the Baseline Visit. 3. Subjects who have been treated with systemic retinoids within 6 months prior to the Baseline visit. 4. Subjects who have participated in a trial involving any investigational product in the 30 days prior to the Baseline Visit. 5. Subjects with any disease or medical condition that would interfere with the study or place the subject at undue risk especially cardiovascular diseases, reduced lung function (including asthma), renal dysfunction or liver dysfunction. 6. Subjects who have been treated within 30 days prior to baseline visit with methadone,disopyramide, dofetilide, dronedarone, quinidine, ergot alkaloids (such as dihydroergotamine, ergometrine (ergonovine), ergotamine, methylergometrine (methylergonovine)), irinotecan, lurasidone, oral midazolam, pimozide, triazolam, felodipine, nisoldipine, ranolazine, eplerenone, cisapride, lovastatin, simvastatin, ticagrelor, terfenadine, astemizole, mizolastine, eletriptan, as well as lovastatin, simvastatin and atorvastatin and, in subjects with varying degrees of renal or hepatic impairment, colchicine, fesoterodine, telithromycin and solifenacin. 7. Subjects who use or have used systemic steroids within the 30 days prior to the Baseline Visit or any other immunosuppressive medication. 8. Subjects positive for human immunodeficiency virus (HIV), hepatitis B and hepatitis C-test at screening. 9. Subjects who are unable to comply with study requirements. 10. Subjects with other skin diseases that may confound the evaluation of rosacea. 11. History of organ transplant requiring immunosuppression, HIV, or other immune compromised state. 12. Subject who in the opinion of the investigator or physician performing the initial examination the subject should not participate in the trial, e.g. due to probable noncompliance or inability to understand the trial and give adequately informed consent 13. Subject with close affiliation with the investigator (e.g. a close relative) or persons working at the respective trial sites or subject who are an employee of sponsor. 14. Subject institutionalized because of legal or regulatory order. 15. History of drug or alcohol abuse in the last year.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in Inflammatory Lesion Counts | At the end of study (12 weeks) | Mean change from Baseline in the inflammatory lesion count at the End of Treatment. A lower score at the end of the study compared to Baseline is considered a better outcome. |
| Number of Subjects With Investigator's Global Assessment (IGA) Success | At the end of study (12 weeks) | Number of subjects with treatment success based on Investigator's Global Assessment (IGA) score at the End of Treatment, defined as an IGA score of 0 (clear) or 1 (almost clear) with composite grade change from Baseline of at least 2 points. |
| Number of Subjects With Treatment Success by Clinician's Erythema Assessment (CEA) Scale | At end of study (12 weeks) | Number of subjects with Treatment Success defined as a score of 0 or 1 and a 2 grade improvement on the CEA scale from Baseline to 12 weeks. |
Countries
Germany
Participant flow
Recruitment details
Subjects were randomized to either DFD-04 Ointment or Placebo Ointment in a ratio of 2:1
Participants by arm
| Arm | Count |
|---|---|
| DFD-04 Ointment DFD-04 (Itraconazole) Ointment | 38 |
| Placebo Ointment Placebo Ointment
t | 23 |
| Total | 61 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Adverse Event | 7 | 2 |
| Overall Study | Protocol Violation | 1 | 0 |
Baseline characteristics
| Characteristic | Placebo Ointment | Total | DFD-04 Ointment |
|---|---|---|---|
| Age, Continuous | 44.3 years STANDARD_DEVIATION 10.2 | 48.1 years STANDARD_DEVIATION 9.4 | 50.4 years STANDARD_DEVIATION 8.1 |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 23 Participants | 61 Participants | 38 Participants |
| Region of Enrollment Germany | 23 participants | 61 participants | 38 participants |
| Sex: Female, Male Female | 18 Participants | 43 Participants | 25 Participants |
| Sex: Female, Male Male | 5 Participants | 18 Participants | 13 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 38 | 0 / 23 |
| other Total, other adverse events | 37 / 38 | 19 / 23 |
| serious Total, serious adverse events | 0 / 38 | 0 / 23 |
Outcome results
Primary
Change in Inflammatory Lesion Counts
Mean change from Baseline in the inflammatory lesion count at the End of Treatment. A lower score at the end of the study compared to Baseline is considered a better outcome.
Time frame: At the end of study (12 weeks)
Population: Intent to Treat (ITT)
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| DFD-04 Ointment | Change in Inflammatory Lesion Counts | -1.4 Number of lesions | Standard Deviation 13.8 |
| Placebo Ointment | Change in Inflammatory Lesion Counts | 2.9 Number of lesions | Standard Deviation 17.5 |
Primary
Number of Subjects With Investigator's Global Assessment (IGA) Success
Number of subjects with treatment success based on Investigator's Global Assessment (IGA) score at the End of Treatment, defined as an IGA score of 0 (clear) or 1 (almost clear) with composite grade change from Baseline of at least 2 points.
Time frame: At the end of study (12 weeks)
Population: Intent to Treat (ITT) population
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| DFD-04 Ointment | Number of Subjects With Investigator's Global Assessment (IGA) Success | 3 participants |
| Placebo Ointment | Number of Subjects With Investigator's Global Assessment (IGA) Success | 2 participants |
Primary
Number of Subjects With Treatment Success by Clinician's Erythema Assessment (CEA) Scale
Number of subjects with Treatment Success defined as a score of 0 or 1 and a 2 grade improvement on the CEA scale from Baseline to 12 weeks.
Time frame: At end of study (12 weeks)
Population: ITT population
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| DFD-04 Ointment | Number of Subjects With Treatment Success by Clinician's Erythema Assessment (CEA) Scale | 2 participants |
| Placebo Ointment | Number of Subjects With Treatment Success by Clinician's Erythema Assessment (CEA) Scale | 2 participants |